
ARCHES | 9785-CL-0335
NCT02677896
JCP011
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)
Status:
Closed to Accrual

III
Phase

Roll over
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Enzalutamide
Nonsteroidal Antiandrogen (p.o.)
Treatment Arms
o Experimental: Enzalutamide + Androgen Deprivation Therapy (ADT)
o Placebo Comparator: Placebo + Androgen Deprivation Therapy (ADT